Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31333036 | 0.88 | BRD4 (0.35) | BRD4PAX8FGFR3KDRAPOBEC3A | |
| SCHEMBL31332914 | 0.76 | BRD4 (0.34) | BRD4PAX8KAT8KAT6AKAT5 | |
| SCHEMBL2767097 | 0.74 | BRD4 (0.34) | BRD4PAX8KAT8KAT6AKAT5 | |
| SCHEMBL3880903 | 0.69 | CDK1 (0.34) | BRD4PAX8KAT8KAT6AKAT5 | |
| SCHEMBL3882903 | 0.69 | BRD4 (0.34) | BRD4PAX8 | |
| SCHEMBL29435491 | 0.68 | ATR (0.39) | BRD4PAX8KAT8KAT6AKAT5 | |
| SCHEMBL3882171 | 0.68 | BRD4 (0.33) | BRD4PAX8 | |
| SCHEMBL2767551 | 0.68 | PAX8 (0.33) | BRD4PAX8 | |
| SCHEMBL15742435 | 0.67 | BRD4 (0.38) | BRD4PAX8 | |
| SCHEMBL23623387 | 0.67 | BRD4 (0.40) | BRD4PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | BRD4 3398/4885FAAH 1776/4885PAX8 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.